Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cerus Corporation    CERS

CERUS CORPORATION (CERS)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
4.32(c) 4.01(c) 4.16(c) 4.11(c) 4.12(c) Last
526 965 1 228 421 551 757 403 057 438 339 Volume
-1.14% -7.18% +3.74% -1.20% +0.24% Change
More quotes
Financials ($)
Sales 2017 44,1 M
EBIT 2017 -59,4 M
Net income 2017 -62,2 M
Finance 2017 20,9 M
Yield 2017 -
Sales 2018 65,2 M
EBIT 2018 -47,5 M
Net income 2018 -49,6 M
Finance 2018 49,8 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 10,2x
EV / Sales2018 6,45x
Capitalization 470 M
More Financials
Company
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products.It produces blood system for platelets and plasma.It markets its products under the INTERCEPT brand.The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is... 
More about the company
Surperformance© ratings of Cerus Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CERUS CORPORATION
01/19 CERUS CORPORATION : Announces Preliminary Product Revenue Results for Fourth Qua..
01/08 CERUS CORPORATION (NASDAQ : CERS) Files An 8-K Results of Operations and Financi..
01/08 CERUS CORP : Results of Operations and Financial Condition, Financial Statements..
01/08 CERUS CORPORATION : Announces Preliminary Product Revenue Results for Fourth Qua..
01/05 CERUS CORP : Change in Directors or Principal Officers, Financial Statements and..
01/04 CERUS : Data from Cerus Corporation Provide New Insights into Arbovirus (Pathoge..
2017 CERUS CORPORATION : Receives IDE Approval to Initiate Phase III ReCePI Study
2017 CERUS : and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEP..
2017 CERUS : Announces Agreement with Transfusion Center of the Community of Madrid
2017 CERUS CORPORATION : Receives IDE Approval to Initiate Phase III ReCePI Study
More news
Sector news : Medical Devices & Implants
01/12 China cracks down on foreign companies calling Taiwan, other regions countrie..
01/12 China cracks down on foreign companies calling Taiwan, other regions countrie..
01/12 Delta, Zara and Medtronic Join Marriott in Beijing's Doghouse After Location ..
01/08 MALLINCKRODT : to Sell Two Hemostasis Products to Baxter
01/07 BAXTER INTERNATIONAL : Hospitals Wrestle With Shortage of IV Bags, Linked to Hur..
More sector news : Medical Devices & Implants
Latest Tweets
01/16TREND REVERSAL DOWN ALERT: $CERS CERUS ? TradeIdeas via  
01/10Cantor Fitzgerald Sets Cerus FY2017 Earnings Estimates at ($0.59) EPS.  
01/09$CERS - Cantor Fitzgerald Reaffirms "Overweight" Rating for Cerus #CERS  
01/09Cantor Fitzgerald Reaffirms “Overweight” Rating for Cerus $CERS  
01/08$CERS Cerus - 424B5 (Prospectus filed pursuant to Rule 424(b)(5)) SEC Filing .. 
More tweets
Qtime:104
News from SeekingAlpha
01/10 YOUR DAILY PHARMA SCOOP : Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides..
01/09 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Bid, Celgene Acquires Impact Biomedici..
01/08 PREMARKET GAINERS AS OF 9 : 05 am
01/05 Premarket analyst action - healthcare
2017 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
Chart CERUS CORPORATION
Duration : Period :
Cerus Corporation Technical Analysis Chart | CERS | US1570851014 | 4-Traders
Technical analysis trends CERUS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 6,00 $
Spread / Average Target 46%
EPS Revisions
Managers
NameTitle
William Mariner Greenman President, Chief Executive Officer & Director
Daniel N. Swisher Chairman
Suzanne Margerum Vice President-Manufacturing & Operations
Kevin Dennis Green Chief Financial Officer & Vice President-Finance
Laurence M. Corash Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CERUS CORPORATION23.08%470
STRYKER CORPORATION3.51%60 357
SMITH & NEPHEW-4.46%15 136
WRIGHT MEDICAL GROUP NV2.25%2 422
JAPAN LIFELINE CO., LTD.8.96%2 105
GLAUKOS CORP15.48%986